Nilotinib Pre and Post Allogeneic Stem Cell Transplantation
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Current therapeutic results in advanced chronic myeloid leukemia (CML) and Ph+ acute
lymphoblastic leukemia (ALL) are rather disappointing. Most of these patients will eventually
undergo allogeneic stem cell transplantation. Nilotinib is a novel TKI tyrosine kinase
inhibitor with 30 fold more potency than Imatinib. Based on previous preliminary experience
the author we rationalize that Nilotinib therapy pre- allogeneic transplantation for patients
with advanced CML and Ph+ALL will reduce tumor mass pre- transplant achieving a state of
minimal residual disease (MRD) and therefore may improve transplantation outcome without
increasing toxicity. In addition it will allow time for improving patient medical condition
and for finding an unrelated donor which will enable allogeneic transplantation , and to
induce anti tumor effect post PBSC w\o DLI ( donor lymphocyte infusion)